Anixa Biosciences (NASDAQ:ANIX) Posts Earnings Results, Beats Expectations By $0.01 EPS

Key Points

• Anixa reported Q results of ($0.08) EPS, beating the consensus ($0.09) by $0.01, and shares traded up about 4.6% to $2.98 after the release.
• Director Arnold M. Baskies purchased 10,000 shares at $3.04, increasing his stake to 135,000 shares and contributing to insiders now owning 26.40% of the stock.
• Analyst views are mixed—three Buys, one Hold and one Sell—giving a consensus rating of “Hold” with a $9.00 price target, while institutional investors own roughly 29.1% of the company.

Anixa Biosciences (NASDAQ:ANIX - Get Free Report) posted its quarterly earnings data on Monday. The company reported ($0.08) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.09) by $0.01, FiscalAI reports.

Anixa Biosciences Stock Up 4.6%

Shares of NASDAQ ANIX traded up $0.13 during trading on Monday, reaching $2.98. The company had a trading volume of 128,478 shares, compared to its average volume of 183,553. Anixa Biosciences has a 12-month low of $2.33 and a 12-month high of $5.46. The business's 50-day moving average is $3.05 and its 200 day moving average is $3.56. The stock has a market cap of $99.47 million, a PE ratio of -8.51 and a beta of 0.48.

Insider Activity

In other news, Director Arnold M. Baskies purchased 10,000 shares of the company's stock in a transaction that occurred on Wednesday, January 28th. The shares were bought at an average price of $3.04 per share, for a total transaction of $30,400.00. Following the purchase, the director directly owned 135,000 shares in the company, valued at approximately $410,400. This trade represents a 8.00% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. 26.40% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the company. NewEdge Advisors LLC bought a new stake in shares of Anixa Biosciences during the second quarter valued at approximately $33,000. Cetera Investment Advisers purchased a new stake in Anixa Biosciences during the 4th quarter valued at $35,000. Northwestern Mutual Wealth Management Co. boosted its stake in Anixa Biosciences by 2,000.0% during the 3rd quarter. Northwestern Mutual Wealth Management Co. now owns 10,500 shares of the company's stock valued at $35,000 after purchasing an additional 10,000 shares during the last quarter. Benjamin Edwards Inc. bought a new stake in shares of Anixa Biosciences in the 2nd quarter worth $37,000. Finally, Millennium Management LLC purchased a new position in shares of Anixa Biosciences in the fourth quarter worth $38,000. Institutional investors own 29.13% of the company's stock.

Analyst Ratings Changes

A number of analysts have recently issued reports on ANIX shares. D. Boral Capital reiterated a "buy" rating and set a $10.00 price target on shares of Anixa Biosciences in a research report on Wednesday, February 4th. Wall Street Zen raised Anixa Biosciences from a "sell" rating to a "hold" rating in a research note on Saturday. Zacks Research lowered Anixa Biosciences from a "strong-buy" rating to a "hold" rating in a research report on Tuesday, November 18th. Finally, Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Anixa Biosciences in a research note on Monday, December 29th. Three research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, Anixa Biosciences currently has an average rating of "Hold" and a consensus price target of $9.00.

Anixa Biosciences Company Profile

Anixa Biosciences is a clinical-stage immuno-oncology and infectious disease company developing novel cell-based immunotherapies and vaccine platforms. Through its Anixa Therapeutics division, the company is advancing antibody and T-cell modalities, including an ovarian cancer immunotherapy candidate and a COVID-19 vaccine leveraging a proprietary virus-like particle (VLP) technology. Its research pipeline emphasizes modular vaccine design and personalized cancer cell therapy aimed at inducing durable immune responses against solid tumors.

In parallel, Anixa Diagnostics is developing the ADAPT diagnostic platform, a high-throughput proteomics approach using engineered peptides derived from spider venom.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.